{"success":true,"data":{"pressRelease":{"id":"88492","rtpr_id":"nPn3TzDlza","ticker":"GRAL","exchange":"NASDAQ","all_tickers":["GRAL"],"title":"INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman","author":"PR Newswire","published_at":"2026-07-15T01:41:00.039Z","article_body":"INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman\n\nPR Newswire\n\nSAN FRANCISCO, July 14, 2026\n\nSAN FRANCISCO, July 14, 2026 /PRNewswire/ -- On February 20, 2026, GRAIL, Inc.\n(NASDAQ: GRAL) shed over $2.2 billion of market capitalization after\nsurprising investors with its NHS-Galleri Trial readout. The news caused huge\ninvestor losses and triggered a securities class action lawsuit seeking to\nrepresent investors who purchased or otherwise acquired shares of GRAIL common\nstock between May 13, 2025 and February 19, 2026.\n\nNational shareholder rights firm Hagens Berman is investigating the alleged\nclaims that GRAIL and its co-defendant executives violated the federal\nsecurities laws and encourages GRAIL investors who suffered substantial losses\nto submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=30806832&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fgral&a=submit+your+losses+now)\n. The firm also encourages persons with knowledge about GRAIL's NHS-Galleri\nTrial to contact the firm's attorneys.\n\nClass Period: May 13, 2025 – Feb. 19, 2026\nLead Plaintiff Deadline: Aug. 4, 2026\nVisit: www.hbsslaw.com/investor-fraud/gral\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=2292152780&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fgral&a=www.hbsslaw.com%2Finvestor-fraud%2Fgral)\n\nContact the Firm Now: GRAL@hbsslaw.com (mailto:GRAL@hbsslaw.com)\n                                       844-916-0895\n\nGRAIL, Inc. (GRAL) Securities Class Action:\n\nCommercial stage healthcare company GRAIL focuses on early cancer detection.\n\nThe litigation focuses on the propriety of GRAIL's disclosures about the\ndesign of its NHS-Galleri trial (the \"trial\") and the likelihood it would meet\nits primary endpoint – with three consecutive years of follow-up screening,\nthe absolute reduction in the number of late stage (stages 3 and 4) cancer\ndiagnoses.\n\nDuring the Class Period, GRAIL expressed high confidence in the trial's design\nand likely outcomes. They consistently stated that the three-year duration was\nspecifically chosen to demonstrate a statistically significant reduction in\ncombined stage 3 and 4 cancers.\n\nThe complaint alleges that GRAIL misled investors by creating the false\nimpression that it possessed reliable information supportive of the\nprobability of the trial achieving its primary endpoint. The complaint further\nalleges that GRAIL's expressed optimism was unrealistic because, unknown to\ninvestors, the company had information suggesting that three years would be\ninsufficient to support the trial's achievement of the primary endpoint.\n\nInvestors learned the truth on February 19, 2026. That day, the defendants\nannounced that the trial failed to achieve its primary endpoint. Of\nsignificant concern was the admission that \"we probably should have allowed\nfor a longer follow-up period.\"\n\nThe market quickly reacted, sending the price of GRAIL shares down over 50%\nthe next day.\n\n\"We're focused on when GRAIL and its management knew that the need for a\nlonger follow-up period diverged from the touted three-year duration,\" said\nReed Kathrein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=3009940440&u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&a=Reed+Kathrein)\n, the Hagens Berman partner leading the firm's investigation of the pending\nclaims in the filed lawsuit.\n\nIf you invested in GRAIL and have substantial losses, or have knowledge that\nwill assist the firm's investigation, submit your losses now.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=254094257&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fgral&a=submit+your+losses+now.)\n\nIf you'd like more information and answers to other frequently asked questions\nabout the GRAIL case and the firm's investigation, read more.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=3499513856&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fgrail-inc-gral-securities-class-action&a=read+more.)\n\nWhistleblowers: Persons with non-public information regarding GRAIL should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email GRAL@hbsslaw.com (mailto:GRAL@hbsslaw.com) .\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=683309500&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=3439498373&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=4154416011&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302825717.html\n(https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302825717.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nReed Kathrein, 844-916-0895\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2763932\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3TzDlza","title":"INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman","author":"PR Newswire","ticker":"GRAL","created":"2026-07-15T01:41:00.039Z","tickers":["GRAL"],"exchange":"NASDAQ","article_body":"INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman\n\nPR Newswire\n\nSAN FRANCISCO, July 14, 2026\n\nSAN FRANCISCO, July 14, 2026 /PRNewswire/ -- On February 20, 2026, GRAIL, Inc.\n(NASDAQ: GRAL) shed over $2.2 billion of market capitalization after\nsurprising investors with its NHS-Galleri Trial readout. The news caused huge\ninvestor losses and triggered a securities class action lawsuit seeking to\nrepresent investors who purchased or otherwise acquired shares of GRAIL common\nstock between May 13, 2025 and February 19, 2026.\n\nNational shareholder rights firm Hagens Berman is investigating the alleged\nclaims that GRAIL and its co-defendant executives violated the federal\nsecurities laws and encourages GRAIL investors who suffered substantial losses\nto submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=30806832&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fgral&a=submit+your+losses+now)\n. The firm also encourages persons with knowledge about GRAIL's NHS-Galleri\nTrial to contact the firm's attorneys.\n\nClass Period: May 13, 2025 – Feb. 19, 2026\nLead Plaintiff Deadline: Aug. 4, 2026\nVisit: www.hbsslaw.com/investor-fraud/gral\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=2292152780&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fgral&a=www.hbsslaw.com%2Finvestor-fraud%2Fgral)\n\nContact the Firm Now: GRAL@hbsslaw.com (mailto:GRAL@hbsslaw.com)\n                                       844-916-0895\n\nGRAIL, Inc. (GRAL) Securities Class Action:\n\nCommercial stage healthcare company GRAIL focuses on early cancer detection.\n\nThe litigation focuses on the propriety of GRAIL's disclosures about the\ndesign of its NHS-Galleri trial (the \"trial\") and the likelihood it would meet\nits primary endpoint – with three consecutive years of follow-up screening,\nthe absolute reduction in the number of late stage (stages 3 and 4) cancer\ndiagnoses.\n\nDuring the Class Period, GRAIL expressed high confidence in the trial's design\nand likely outcomes. They consistently stated that the three-year duration was\nspecifically chosen to demonstrate a statistically significant reduction in\ncombined stage 3 and 4 cancers.\n\nThe complaint alleges that GRAIL misled investors by creating the false\nimpression that it possessed reliable information supportive of the\nprobability of the trial achieving its primary endpoint. The complaint further\nalleges that GRAIL's expressed optimism was unrealistic because, unknown to\ninvestors, the company had information suggesting that three years would be\ninsufficient to support the trial's achievement of the primary endpoint.\n\nInvestors learned the truth on February 19, 2026. That day, the defendants\nannounced that the trial failed to achieve its primary endpoint. Of\nsignificant concern was the admission that \"we probably should have allowed\nfor a longer follow-up period.\"\n\nThe market quickly reacted, sending the price of GRAIL shares down over 50%\nthe next day.\n\n\"We're focused on when GRAIL and its management knew that the need for a\nlonger follow-up period diverged from the touted three-year duration,\" said\nReed Kathrein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=3009940440&u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&a=Reed+Kathrein)\n, the Hagens Berman partner leading the firm's investigation of the pending\nclaims in the filed lawsuit.\n\nIf you invested in GRAIL and have substantial losses, or have knowledge that\nwill assist the firm's investigation, submit your losses now.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=254094257&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fgral&a=submit+your+losses+now.)\n\nIf you'd like more information and answers to other frequently asked questions\nabout the GRAIL case and the firm's investigation, read more.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=3499513856&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fgrail-inc-gral-securities-class-action&a=read+more.)\n\nWhistleblowers: Persons with non-public information regarding GRAIL should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email GRAL@hbsslaw.com (mailto:GRAL@hbsslaw.com) .\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=683309500&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=3439498373&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731920-1&h=4154416011&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302825717.html\n(https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302825717.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nReed Kathrein, 844-916-0895\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2763932\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-15T01:41:00.102660503Z","server_sent_at_ms":1784079660102},"received_at":"2026-07-15T01:41:00.169Z","source_url":"https://www.prnewswire.com/news-releases/investor-notice-grail-inc-gral-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-hagens-berman-302825717.html"},"analysis":{"id":"77546","press_release_id":"88492","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Hagens Berman issued a shareholder-solicitation notice regarding GRAIL, investigating potential federal securities violations tied to the NHS-Galleri trial readout.\n\nThe firm reminds investors of the August 4, 2026 lead plaintiff deadline for the class period between May 13, 2025 and February 19, 2026.\n\nThis release is a law-firm marketing solicitation, not an issuer disclosure, and should be treated as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"We're focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration,","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Partner at Hagens Berman"}],"products":["NHS-Galleri"],"companies":[{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm"},{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"target"}],"dollarAmounts":[{"amount":"$2.2 billion","context":"market capitalization shed after trial readout"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Hagens Berman. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GRAL"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman issued a shareholder-solicitation notice regarding GRAIL, investigating potential federal securities violations tied to the NHS-Galleri trial readout.\n\nThe firm reminds investors of the August 4, 2026 lead plaintiff deadline for the class period between May 13, 2025 and February 19, 2026.\n\nThis release is a law-firm marketing solicitation, not an issuer disclosure, and should be treated as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Partner at Hagens Berman"}],"products":["NHS-Galleri"],"companies":[{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm"},{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"target"}],"dollarAmounts":[{"amount":"$2.2 billion","context":"market capitalization shed after trial readout"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-15T01:41:55.447Z","global_importance":15,"audience_relevance":10,"importance_components":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":55269,"modelName":"glm-4.7"}}